The Online Investor
Drugs & Pharmaceuticals M&A image Drugs & Pharmaceuticals M&A » By The Online Investor Staff, updated Tue., Dec. 6, 9:48 AM Recent mergers and acquisitions in the Drugs & Pharmaceuticals M&A category.

Slide #57. Pfizer Polocard

Acquirer: Pfizer (NYSE:PFE)
Acquiree: Polocard
Details: Pfizer Inc. (NYSE:PFE) today announced that a wholly-owned Polish subsidiary of Pfizer has acquired the rights to Polocard, a low-dose aspirin (acidum acetylsalicylicum), and the leading over-the-counter (OTC) brand for heart attack prevention in Poland, from ZF Polpharma SA.

Pfizer is a research-based, global biopharmaceutical company. Co. is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Co. collaborates with healthcare providers, governments and local communities to support and expand access to healthcare around the world. Co. provides vaccines across various ages (infants, adolescents and adults) in pneumococcal disease, meningococcal disease, tick-borne encephalitis and novel coronavirus disease of 2019 (COVID-19). Key products include: Comirnaty/BNT162b2, the Prevnar family, Nimenrix, FSME/IMMUN-TicoVac and Trumenba.

Pfizer SEC Filing Email Alerts Service


Open the PFE Page at The Online Investor »

Company Name: 
Pfizer Inc
Stock buyback: 
PFE buyback
Website: 
www.pfizer.com
Sector: 
Drugs & Pharmaceuticals
Number of ETFs Holding PFE: 
130
Total Market Value Held by ETFs: 
$36.64B
Total Market Capitalization: 
$67.34B
% of Market Cap. Held by ETFs: 
54.41%
 

Open the PFE Page at The Online Investor (in a new window) »

Quotes delayed 20 minutes

Email EnvelopeFree PFE Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts

Buy (3.27 out of 4)
39th percentile
(ranked lower than approx. 61% of all stocks covered)

Analysts' Target Price:
PFE Stock Forecast

Based on Zacks ABR data;
powered by Xignite

Drugs & Pharmaceuticals M&A - Slide 57 of 100 Page | www.TheOnlineInvestor.com

Copyright © 1998 - 2022, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.